KPRX · Kiora Pharmaceuticals Inc
United States · RS rating 17 · As of 2026-11-03
| Price | 1.73 USD |
|---|---|
| 1-day change | +6.1% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 11 / 19 / 34 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 25 / 17 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +41.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +39.5% |
| Market cap (USD) | $10.5M |